Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice

Journal of Clinical Investigation

Volumn 120, Issue 8, 2010, Pages 2910-2919

  Hanson, Julien ^a,b,c   Gille, Andreas ^b,f   Zwykiel, Sabrina ^b   Lukasova, Martina ^a,b   Clausen, Björn E ^d   Ahmed, Kashan ^a,b   Tunaru, Sorin ^a,b   Wirth, Angela ^a,b   Offermanns, Stefan ^a,b,e  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e GOETHE UNIVERSITY   (Germany)

^f CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FR 122047; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; METHYL FUMARATE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NICOTINIC ACID; PROSTAGLANDIN E2; PROSTANOID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TYPE; CONTROLLED STUDY; ENZYME INHIBITION; EPIDERMIS CELL; FLUSHING; GENE ACTIVATION; HUMAN; HUMAN CELL; KERATINOCYTE; LANGERHANS CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; FLUSHING; FUMARATES; HUMANS; KERATINOCYTES; LANGERHANS CELLS; MICE; MICE, INBRED C57BL; NIACIN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC;

EID: 77955300428     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42273     Document Type: Article

References (55)

1. Canner PL, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-1255.
2. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258(2):94-114.
3. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol. 2004;15(6):659-665.
4. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol. 2008;48:79-106.
5. Digby JE, Lee JM, Choudhury RP. Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol. 2009;20(4):321-326.
6. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol. 2008;101(8A):58B-62B.
7. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract. 2009;63(9):1369-1377.
8. Davidson MH. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol. 2008;101(8A):14B-19B.
9. Spies TD, Cooper C, Blankenhorn MA. The use of nicotinic acid in the treatment of pellagra. JAMA. 1938;110(9):622-627.
10. Fouts PJ, Helmer OM, Lepkovsky L, Jukes TH. Treatment of human pellegra with nicotinic acid. Proc Soc Exp Biol Med. 1937;37:405-407.
11. Goldsmith GA, Cordill S. The vasodilating effects of nicotinic acid (Relation to metabolic rate and body temperature). Am J Med Sci. 1943;205(2):204-208.
12. Benyo Z, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005;115(12):3634-3640.
13. Andersson RG, Aberg G, Brattsand R, Ericsson E, Lundholm L. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol (Copenh). 1977;41(1):1-10. (Pubitemid 8150983)
14. Eklund B, Kaijser L, Nowak J, Wennmalm A. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins. 1979;17(6):821-830.
15. Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol. 1979;57(2):114-117.
16. Morrow JD, Parsons WG 3rd, Roberts LJ 2nd. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989; 38(2):263-274.
17. Stern RH, Spence JD, Freeman DJ, Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther. 1991;50(1):66-70.
18. Cheng K, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103(17):6682-6687.
19. Paolini JF, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101(5):625-630.
20. Bays HE, Ballantyne C. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol. 2009;20(6):467-476.
21. Perry CM. Extended-release niacin (nicotinic acid)/ laropiprant. Drugs. 2009;69(12):1665-1679.
22. Benyo Z, Gille A, Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol. 2006;70(6):1844-1849.
23. Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol. 2006;126(12):2637-2646.
24. Rostami Yazdi M, Mrowietz U. Fumaric acid esters. Clin Dermatol. 2008;26(5):522-526.
25. Tang H, Lu JY, Zheng X, Yang Y, Reagan JD. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008;375(4):562-565.
26. Bennett CL, et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol. 2005;169(4):569-576.
27. Ochi T, Motoyama Y, Goto T. The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. Eur J Pharmacol. 2000;391(1-2):49-54.
28. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/ cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994;47(1):55-59.
29. Edlund A, Musatti L, Wennmalm A. Acipimox stimulates skin blood flow by a cyclo-oxygenase- dependent mechanism. Eur J Clin Pharmacol. 1990;39(1):37-41.
30. Tunaru S, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003;9(3):352-355.
31. Semple G, et al. 3-(1H-tetrazol-5-yl)-1,4,5, 6-tetrahydro- cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J Med Chem. 2008;51(16):5101-5108.
32. Walters RW, et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest. 2009;119(5):1312-1321.
33. Schaub A, Futterer A, Pfeffer K. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur J Immunol. 2001; 31(12):3714-3725.
34. Yousefi S, Cooper PR, Mueck B, Potter SL, Jarai G. cDNA representational difference analysis of human neutrophils stimulated by GM-CSF. Biochem Biophys Res Commun. 2000;277(2):401-409.
35. Thorburn J, Frankel AE, Thorburn A. Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein. Clin Cancer Res. 2003;9(2):861-865.
36. Morimoto H, Bonavida B. Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. J Immunol. 1992; 149(6):2089-2094.
37. Muller-Decker K, Scholz K, Neufang G, Marks F, Furstenberger G. Localization of prostaglandin-H synthase-1 and -2 in mouse skin: implications for cutaneous function. Exp Cell Res. 1998;242(1):84-91.
38. Wilgus TA, Ross MS, Parrett ML, Oberyszyn TM. Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid Mediat. 2000;62(4):367-384.
39. Akunda JK, Lao HC, Lee CA, Sessoms AR, Slade RM, Langenbach R. Genetic deficiency or pharmacological inhibition of cyclooxygenase-1 or -2 induces mouse keratinocyte differentiation in vitro and in vivo. FASEB J. 2004;18(1):185-187.
40. Leong J, Hughes-Fulford M, Rakhlin N, Habib A, Maclouf J, Goldyne ME. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Exp Cell Res. 1996;224(1):79-87.
41. Pentland AP, Needleman P. Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis. J Clin Invest. 1986;77(1):246-251.
42. Jonsson CE, Anggard E. Biosynthesis and metabolism of prostaglandin E 2 in human skin. Scand J Clin Lab Invest. 1972;29(3):289-296.
43. Williams TJ, Peck MJ. Role of prostaglandin-mediated vasodilatation in inflammation. Nature. 1977;270(5637):530-532.
44. Rosenbach T, Czernielewski J, Hecker M, Czarnetzki B. Comparison of eicosanoid generation by highly purified human Langerhans cells and keratinocytes. J Invest Dermatol. 1990;95(1):104-107.
45. Ujihara M, Horiguchi Y, Ikai K, Urade Y. Characterization and distribution of prostaglandin D synthetase in rat skin. J Invest Dermatol. 1988;90(4):448-451.
46. Dishy V, et al. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol. 2009;49(4):416-422.
47. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311(19):1206-1211.
48. Cerletti C, et al. Pharmacokinetics of enteric-coated aspirin and inhibition of platelet thromboxane A2 and vascular prostacyclin generation in humans. Clin Pharmacol Ther. 1987;42(2):175-180.
49. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993;90(24):11693-11697.
50. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.
51. Wirth A, et al. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for saltinduced hypertension. Nat Med. 2008;14(1):64-68.
52. Muyrers JP, Zhang Y, Testa G, Stewart AF. Rapid modification of bacterial artificial chromosomes by ET-recombination. Nucleic Acids Res. 1999; 27(6):1555-1557.
53. Moers A, et al. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med. 2003;9(11):1418-1422.
54. Lichti U, Anders J, Yuspa SH. Isolation and shortterm culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice. Nat Protoc. 2008;3(5):799-810.
55. Baubet V, Le Mouellic H, Campbell AK, Lucas- Meunier E, Fossier P, Brulet P. Chimeric green fluorescent protein-aequorin as bioluminescent Ca2+ reporters at the single-cell level. Proc Natl Acad Sci U S A. 2000;97(13):7260-7265.